Showing 581-590 of 20377 results for "".
CGM in the Real T2D World
https://reachmd.com/programs/cme/cgm-real-t2d-world/50982/Continuous glucose monitoring (CGM) is still recommended for all individuals with diabetes, including those with type 2 diabetes (T2D). Despite this, its use in managing T2D has not been as widespread as expected. New evidence has recently highlighted the benefits of CGM for people with T2D. Join ouUtilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients
https://reachmd.com/programs/diabetes-discourse/utilizing-hybrid-closed-loop-technology-for-t1d-pediatric-patients/17885/Tune in to learn about a recent study on hybrid closed-loop technology in young children with type 1 diabetes.Toward Safe and Effective Insulin Initiation
https://reachmd.com/programs/diabetes-discourse/toward-safe-and-effective-insulin-initiation/4579/Type 2 diabetes is a progressive disease and most patients will eventually need insulin to achieve euglycemia. Early and aggressive management to lower blood glucose reduces the risk of complications of the disease. It can be challenging for health care professionals to decide which treatment regimeDo We Need to Temper our Enthusiasm for Incretin-Based Therapy?
https://reachmd.com/programs/diabetes-discourse/do-we-need-to-temper-our-enthusiasm-for-incretin-based-therapy/5947/There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and hiGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
https://reachmd.com/programs/neurofrontiers/gfap-and-vegf-trajectories-in-adult-type-3-spinal-muscular-atrophy-under-nusinersen/54637/Sexual Dysfunction: Communication is the Key
https://reachmd.com/programs/diabetes-discourse/sexual-dysfunction-communication-is-the-key/4603/A certified diabetes educator can help both physicians and patients when it comes to sexual dysfunction. Sexual dysfunction is experienced by over half of all women with diabetes, and approximately 32 percent of men with type 1 and 46 percent of men with type 2. So, it is critical to provide good coClosing Gaps in Care for Patients with T2D & CV Disease
https://reachmd.com/programs/diabetes-discourse/closing-gaps-in-care-for-patients-with-t2d-cv-disease/15148/Learn more about obstacles to care for patients with type 2 diabetes and cardiovascular disease from the recent COORDINATE study.Managing Obesity & Pre-Diabetes When Lifestyle Modifications Fail
https://reachmd.com/programs/primary-care-today/managing-obesity-pre-diabetes-when-lifestyle-modifications-fail/7818/What options are available to our patients at risk of diabetes after other modifications fall short of target goals?Risk Reduction with GLP-1 RAs in Individuals with ASCVD and T2D: 2025 Update
https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many indivNew Developments in Incretins and SGLT Inhibitors
https://reachmd.com/programs/diabetes-discourse/new-developments-in-incretins-and-sglt-inhibitors/4694/The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gast